Ultragenyx Settles Dojolvi Patent Litigation With Navinta
Bitget2026/10/19 13:08- Ultragenyx Pharmaceutical and Baylor Research Institute settled DOJOLVI patent litigation with Navinta on October 19, 2026.
- Navinta will receive a non-exclusive, royalty-free license to market generic DOJOLVI beginning January 1, 2033, subject to customary conditions and exceptions.
- The launch date would move to July 1, 2033, if DOJOLVI receives pediatric exclusivity.
- The litigation stemmed from Navinta's application for FDA approval of a generic version of DOJOLVI oral liquid.
- Similar DOJOLVI patent litigation against other generic applicants remains pending in the U.S. District Court for the District of New Jersey.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Strong earnings report can't stop sell-off! Credit concerns intensify as US bank stocks record longest losing streak since 2008
Although the financial reports released so far by some of the largest banks in the United States remain robust, U.S. bank stocks are currently experiencing their longest period of decline since the 2008 financial crisis.
3M (MMM.US) issues 3.16 million warrants to Amazon, expanding data center product cooperation
Shares of 3M rose after the company announced an expanded partnership with Amazon Data Center products.
Palantir (PLTR.US) partners with cloud custody service provider Knox to accelerate cloud deployment of critical software for the U.S. government
Palantir announced a new agreement with cloud custody service provider Knox Systems on Monday to deliver software services to the U.S. federal government via the cloud.
Crypto prices
More
